CN110719788A - 治疗实体瘤的沙粒病毒颗粒 - Google Patents

治疗实体瘤的沙粒病毒颗粒 Download PDF

Info

Publication number
CN110719788A
CN110719788A CN201880038230.3A CN201880038230A CN110719788A CN 110719788 A CN110719788 A CN 110719788A CN 201880038230 A CN201880038230 A CN 201880038230A CN 110719788 A CN110719788 A CN 110719788A
Authority
CN
China
Prior art keywords
arenavirus
tumor
antigen
kit
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880038230.3A
Other languages
English (en)
Chinese (zh)
Inventor
克劳斯·奥尔林格
莎拉·施密特
艾哈迈德·埃尔-加扎尔
卢卡斯·罗兰·弗拉茨
桑德拉·斯蒂芬妮·林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hookipa Biotech GmbH
Original Assignee
Hookipa Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech GmbH filed Critical Hookipa Biotech GmbH
Publication of CN110719788A publication Critical patent/CN110719788A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880038230.3A 2017-04-07 2018-04-06 治疗实体瘤的沙粒病毒颗粒 Pending CN110719788A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483067P 2017-04-07 2017-04-07
US62/483,067 2017-04-07
PCT/EP2018/058900 WO2018185307A1 (en) 2017-04-07 2018-04-06 Arenavirus particles to treat solid tumors

Publications (1)

Publication Number Publication Date
CN110719788A true CN110719788A (zh) 2020-01-21

Family

ID=62025795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880038230.3A Pending CN110719788A (zh) 2017-04-07 2018-04-06 治疗实体瘤的沙粒病毒颗粒

Country Status (7)

Country Link
US (1) US20200113995A1 (https=)
EP (1) EP3606549A1 (https=)
JP (1) JP2020516601A (https=)
CN (1) CN110719788A (https=)
AU (1) AU2018247958A1 (https=)
CA (1) CA3058539A1 (https=)
WO (1) WO2018185307A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115197965A (zh) * 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
CN116218681A (zh) * 2022-08-02 2023-06-06 汕头大学 三角褐指藻钙网蛋白基因过表达突变株的构建方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
CN115058452A (zh) 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
LT3218504T (lt) 2014-11-13 2020-09-10 Université De Geneve Trijų segmentų arenavirusai kaip vakcinos vektoriai
IL314371A (en) 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
RS63546B1 (sr) 2015-11-12 2022-09-30 Hookipa Biotech Gmbh Čestice arenavirusa kao vakcine protiv kancera
MX2022014725A (es) * 2020-05-29 2023-02-09 Hookipa Biotech Gmbh Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus.
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
US20240229073A1 (en) * 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors
CA3236106A1 (en) 2021-11-08 2023-05-11 Henning Lauterbach Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
TW202346363A (zh) * 2022-03-16 2023-12-01 德商百靈佳殷格翰國際股份有限公司 腫瘤抗原、包含所述腫瘤抗原的化合物及其用途
CN115192709B (zh) * 2022-05-12 2023-07-21 黄淮学院 O-GlcNAc糖基转移酶抑制剂在制备抑制精子发生的药物中的用途
WO2025101837A1 (en) * 2023-11-10 2025-05-15 Eccletech Llc Biological devices and methods of using the same for detection of different types of cancer
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127501A1 (en) * 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
WO2016075250A1 (en) * 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors
WO2016166285A1 (de) * 2015-04-17 2016-10-20 Lang Karl Sebastian Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften
WO2016170176A1 (en) * 2015-04-22 2016-10-27 Curevac Ag Rna containing composition for treatment of tumor diseases
WO2016198531A2 (en) * 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
CN108697775A (zh) * 2015-11-12 2018-10-23 霍欧奇帕生物科技股份公司 作为癌症疫苗的沙粒病毒颗粒
CN109804074A (zh) * 2016-05-18 2019-05-24 巴塞尔大学 作为疫苗载体的三区段pichinde病毒
CN110167586A (zh) * 2016-11-04 2019-08-23 霍欧奇帕生物科技有限公司 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
MXPA05003395A (es) * 2002-10-03 2005-06-22 Wyeth Corp Polipeptidos de virus de papiloma humano y composiciones inmunogenas.
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2604695B1 (en) * 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127501A1 (en) * 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
WO2016075250A1 (en) * 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors
WO2016166285A1 (de) * 2015-04-17 2016-10-20 Lang Karl Sebastian Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften
WO2016170176A1 (en) * 2015-04-22 2016-10-27 Curevac Ag Rna containing composition for treatment of tumor diseases
WO2016198531A2 (en) * 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
CN108697775A (zh) * 2015-11-12 2018-10-23 霍欧奇帕生物科技股份公司 作为癌症疫苗的沙粒病毒颗粒
CN109804074A (zh) * 2016-05-18 2019-05-24 巴塞尔大学 作为疫苗载体的三区段pichinde病毒
CN110167586A (zh) * 2016-11-04 2019-08-23 霍欧奇帕生物科技有限公司 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HALIME KALKAVAN等: "Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferondependent tumour regression", NATURE COMMUNICATIONS, no. 8, 1 March 2017 (2017-03-01), pages 1 - 14 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115197965A (zh) * 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
CN116218681A (zh) * 2022-08-02 2023-06-06 汕头大学 三角褐指藻钙网蛋白基因过表达突变株的构建方法

Also Published As

Publication number Publication date
WO2018185307A1 (en) 2018-10-11
US20200113995A1 (en) 2020-04-16
JP2020516601A (ja) 2020-06-11
AU2018247958A1 (en) 2019-10-10
EP3606549A1 (en) 2020-02-12
CA3058539A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
CN110719788A (zh) 治疗实体瘤的沙粒病毒颗粒
CN108697775B (zh) 作为癌症疫苗的沙粒病毒颗粒
AU2021232660B2 (en) HPV vaccines
AU2017353443B2 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
AU2014359276B2 (en) CMV vaccines
Qiu et al. Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8+ T-cell response and protects mice from melanoma
CN107223130A (zh) 作为疫苗载体的三片段沙粒病毒
US20250073324A1 (en) Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
US20260061044A1 (en) Mutated Influenza Virus, Pharmaceutical Composition, and Use
WO2025191169A1 (en) Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies
CN118450900A (zh) 作为癌症免疫疗法的表达突变kras、突变癌症驱动基因或肿瘤相关抗原的经修饰的沙粒病毒颗粒
HK1260579B (en) Arenavirus particles as cancer vaccines
HK1260579A1 (en) Arenavirus particles as cancer vaccines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200121